Radiologists, meanwhile, took to social media to criticize the endeavor, noting that the generative AI company lacks clinical evidence to back its marketing claims.
The proportion of radiologists performing some (>0%) IR-related work declined from 70% in 2008 down to 50% by 2023, according to new research published in JVIR.
An ongoing study is evaluating how capably two PSMA agents assess urinary radioactivity and identify smaller lesions in post-prostatectomy patients with low PSA biochemical recurrence.
The petition from Harrison.ai has drawn mixed reactions, with AI vendors lending support while radiologists and patient groups worry the move could erode safety.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.
A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.
